MX2025012580A - Un factor de von willebrand recombinante (vwf) y el uso en hemorragia gastrointestinal - Google Patents

Un factor de von willebrand recombinante (vwf) y el uso en hemorragia gastrointestinal

Info

Publication number
MX2025012580A
MX2025012580A MX2025012580A MX2025012580A MX2025012580A MX 2025012580 A MX2025012580 A MX 2025012580A MX 2025012580 A MX2025012580 A MX 2025012580A MX 2025012580 A MX2025012580 A MX 2025012580A MX 2025012580 A MX2025012580 A MX 2025012580A
Authority
MX
Mexico
Prior art keywords
von willebrand
patients
administration
treatment
gastrointestinal bleeding
Prior art date
Application number
MX2025012580A
Other languages
English (en)
Spanish (es)
Inventor
Miranda Chapman
Bruce Ewenstein
Bettina Ploder
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2025012580A publication Critical patent/MX2025012580A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2025012580A 2017-07-07 2020-01-08 Un factor de von willebrand recombinante (vwf) y el uso en hemorragia gastrointestinal MX2025012580A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762530027P 2017-07-07 2017-07-07
PCT/US2018/041320 WO2019010497A1 (en) 2017-07-07 2018-07-09 TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH A SEVERE FORM OF VON WILLEBRAND'S DISEASE BY RECOMBINANT VWF ADMINISTRATION

Publications (1)

Publication Number Publication Date
MX2025012580A true MX2025012580A (es) 2026-01-07

Family

ID=63036433

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025012580A MX2025012580A (es) 2017-07-07 2020-01-08 Un factor de von willebrand recombinante (vwf) y el uso en hemorragia gastrointestinal

Country Status (16)

Country Link
US (5) US10632176B2 (enExample)
EP (2) EP3648788B1 (enExample)
JP (2) JP7307047B2 (enExample)
KR (2) KR20260037107A (enExample)
CN (1) CN111436193A (enExample)
AU (2) AU2018298233B2 (enExample)
BR (1) BR112020000321A2 (enExample)
CA (1) CA3069295A1 (enExample)
CO (1) CO2020001322A2 (enExample)
DK (1) DK3648788T3 (enExample)
ES (1) ES2986574T3 (enExample)
FI (1) FI3648788T5 (enExample)
MX (1) MX2025012580A (enExample)
PL (1) PL3648788T3 (enExample)
PT (1) PT3648788T (enExample)
WO (1) WO2019010497A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3648788T5 (fi) 2017-07-07 2024-09-09 Takeda Pharmaceuticals Co Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää
JP7326246B2 (ja) 2017-07-07 2023-08-15 武田薬品工業株式会社 待機手術を受ける、重度のフォンヴィレブランド病を患う患者の、組換えｖｗｆの投与による治療法
US20220395560A1 (en) * 2019-02-01 2022-12-15 Takeda Pharmaceutical Company Limited METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF)
EA202192140A1 (ru) * 2019-02-01 2021-12-15 Такеда Фармасьютикал Компани Лимитед СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
WO2021032646A1 (en) * 2019-08-16 2021-02-25 Octapharma Ag Stabilizing buffer for factor viii and vwf

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
WO1986006096A1 (en) 1985-04-11 1986-10-23 The Children's Medical Center Corporation Von willebrand factor
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US6005077A (en) 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
WO2004039337A2 (en) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
WO2005012354A1 (en) 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
AU2005322067B8 (en) 2004-12-27 2012-07-26 Takeda Pharmaceutical Company Limited Polymer-von Willebrand factor-conjugates
ES2474573T3 (es) 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
PL2167117T3 (pl) 2007-06-13 2013-01-31 Csl Behring Gmbh Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi
AU2008323768A1 (en) 2007-11-09 2009-05-14 Baxter Healthcare S.A. Modified recombinant Factor VIII and von Willebrand Factor and methods of use
EP2244814B1 (en) 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Recombinant vwf formulations
EP2865760B1 (en) 2008-06-24 2017-10-11 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
US20110072524A1 (en) 2009-08-04 2011-03-24 Baxter International Inc. Transgenic Mouse Lacking Endogenous FVIII and VWF - A Model of Hemophilia A
EA202090067A3 (ru) 2010-07-08 2020-07-31 Баксалта Инкорпорейтид Способ получения рекомбинантного adamts13 в культуре клеток
CN103732244A (zh) 2011-06-10 2014-04-16 巴克斯特国际公司 通过施用重组vwf治疗凝血疾病
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
FI3648788T5 (fi) 2017-07-07 2024-09-09 Takeda Pharmaceuticals Co Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää

Also Published As

Publication number Publication date
FI3648788T3 (fi) 2024-08-16
PT3648788T (pt) 2024-08-23
JP7307047B2 (ja) 2023-07-11
KR20200037235A (ko) 2020-04-08
PL3648788T3 (pl) 2024-10-07
US20230122958A1 (en) 2023-04-20
CA3069295A1 (en) 2019-01-10
US10632176B2 (en) 2020-04-28
EP3648788B1 (en) 2024-05-22
AU2025205392A1 (en) 2025-09-25
RU2020105682A3 (enExample) 2021-10-15
RU2020105682A (ru) 2021-08-10
JP2020526525A (ja) 2020-08-31
DK3648788T3 (da) 2024-08-19
JP7641327B2 (ja) 2025-03-06
US11529395B2 (en) 2022-12-20
US20190091299A1 (en) 2019-03-28
US20240316160A1 (en) 2024-09-26
BR112020000321A2 (pt) 2020-07-14
US12016904B2 (en) 2024-06-25
JP2023123738A (ja) 2023-09-05
EP3648788A1 (en) 2020-05-13
KR20260037107A (ko) 2026-03-17
US20210169989A1 (en) 2021-06-10
US10905746B2 (en) 2021-02-02
ES2986574T3 (es) 2024-11-12
EP4424366A2 (en) 2024-09-04
US20200206318A1 (en) 2020-07-02
EP4424366A3 (en) 2024-12-04
AU2018298233A1 (en) 2020-01-30
WO2019010497A1 (en) 2019-01-10
CN111436193A (zh) 2020-07-21
KR102921337B1 (ko) 2026-02-02
AU2018298233B2 (en) 2025-04-24
CO2020001322A2 (es) 2020-02-18
FI3648788T5 (fi) 2024-09-09

Similar Documents

Publication Publication Date Title
EP4424366A3 (en) Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
CL2022002836A1 (es) Polipeptidos derivados de cancer (divisional 201902533)
MX2020000083A (es) Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand.
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
FI3227675T3 (fi) Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi
EA201890507A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
MX384378B (es) Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca.
FI3261661T3 (fi) Menotropiini hedelmättömyyden hoitamiseksi
MY204827A (en) Semaglutide in medical therapy
RU2017128296A (ru) Композиция для лечения бесплодия
CO2021011340A2 (es) Métodos de tratamiento profiláctico con vwf recombinante (rvwf)
PH12015502100A1 (en) Reducing the risk of autoimmune disease
MX2024004333A (es) Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.
CO2020001314A2 (es) Tratamiento de pacientes con enfermedad de von willebrand grave que se someten a cirugía electiva mediante administración de vwf recombinante
JP2014530246A5 (enExample)
MX2022005448A (es) Método de tratamiento de queratodermia palmoplantar.
AR090095A1 (es) Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
EA201291384A1 (ru) Терапевтические агенты 976
MX2022009492A (es) Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de factor de von willebrand (fvw) recombinante.
RU2022116119A (ru) Лечение желудочно-кишечного кровотечения у пациентов с тяжелой формой болезни фон виллебранда путем введения рекомбинантного ффв
AR118608A2 (es) TRATAMIENTO DE LOS TRASTORNOS DE LA COAGULACIÓN MEDIANTE LA ADMINISTRACIÓN DE UN FACTOR DE VON WILLEBRAND (vWF) RECOMBINANTE
RU2015147544A (ru) Пролонгированный фактор эритропоэза человека и лекарственное средство на его основе
Bravo et al. VWF modulates the in vivo FVIII recovery of different FVIII concentrates in a mice model of severe hemophilia with inhibitors
MX2021004511A (es) Medicamento para el tratamiento y/o mejora de la septicemia asociada con la anomalia de la coagulacion.
AR118192A1 (es) ADMINISTRACIÓN DE b-SARCOGLICANO CON UN VECTOR DE VIRUS ADENOASOCIADO Y TRATAMIENTO DE LA DISTROFIA MUSCULAR